LR Health & Beauty invests in the support of its sales partners
14.5.2019 14:18:00 EEST | Business Wire | Press release
LR Health & Beauty continuously invests in the development of modern sales concepts which enable the partners to successfully set up and expand their businesses. The company has now launched the innovative tool "LR MyOffice" to support sales partners with their work in the digital LR world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005504/en/
LR Health & Beauty invests in the support of its sales partners (Photo: Business Wire)
Transparent, simple and compatible with all devices
In cooperation with the American software provider Exigo, the direct sales company from Ahlen was able to take digitalisation to the next level. Thanks to "LR MyOffice" sales partners can get information on all relevant business figures and activities at a glance – the data is updated around the clock. What turnover have I achieved thus far this month? How are my team members developing? Are there persons in my team who soon celebrate their birthday or jubilee, whom I can congratulate? "LR MyOffice" has the answers and works as a personal assistant. "The programme helps LR partners to better understand their business figures and to control their business activities", says Andreas Friesch, CEO and management spokesman of LR. Furthermore, the tool runs on all terminal devices – not only on the PC at home but also on tablets and smartphones.
Clear activity orientation for new partners and professionals
The special feature of "LR MyOffice" is that every partner sees at first glance what he and his team members have to do to reach the next bonus or career level. Thanks to easy application, even novices manage the tool with ease and are able to quickly manage their LR business independently. The tool box enables profs to exploit opportunities with regard to structure and daily routine even more efficiently. "We were very pleased to partner with LR to leverage our technical expertise and platform, to create the new tool for LR's partners", says Ed Jarrin, President of Exigo.
Positive feedback in the prelaunch phase
The prelaunch phase started last February – from 14 May, the tool will be available for all LR sales partners. "From my point of view, 'LR MyOffice' has already proved its worth. The partners who used the tool in the prelaunch phase are simply impressed", says Friesch contently. In the course of the next few months, new functions will be added to the programme.
LR Health & Beauty
Under the motto “More quality for your life“, the LR Group with headquarters in Ahlen/Westphalia produces and markets various health and beauty products in around 28 countries. The range includes care and decorative cosmetics, dietary supplements and perfumes. LR Health & Beauty attaches great importance to the processing of premium raw materials. As most articles are manufactured at the Ahlen site, the company stands for top products "made in Germany". The processing of Aloe Vera has been one of the core competencies of LR Health & Beauty for more than 15 years. Only the valuable inside of the leaf is used for the products. With a volume of 12,000 tonnes of Aloe Vera leafs per year, LR is among the world’s largest manufacturers of Aloe Vera products. In Ahlen, the company has established the most modern Aloe Vera production site for Aloe Vera Drinking Gels in Europe. With 1,100 employees as well as thousands of registered sales partners and customers, LR is one of Europe’s leading direct sales enterprises. LR's strong market position is based above all on a high-quality product range and an attractive bonus and training plan which is unsurpassed in the industry. LR also established the LR Global Kids Fund e. V. which provides efficient and unbureaucratic support for deprived children and their families in many different countries around the world in cooperation with local institutions.
Exigo
Exigo is the leading global technology provider in the direct selling industry. Exigo supports 100 direct selling companies around the world, which include 12 of the 2019 DSN Global Top 100 direct sales companies. Exigo’s global clients operate in over 120 countries, 40 currencies and 30 languages.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005504/en/
Contact information
LR Health & Beauty
Almut Kellermeyer
Head of PR / Public
Affairs
Tel: +49 2382 7060-114
Email: a.kellermeyer@LRworld.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
